Completed OBSERVATIONAL NCT01287351

Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study (USQvarAsthma)

Retrospective, Real-life Observational Evaluation of the Effectiveness and Cost-effectiveness of Extra-fine Hydrofluoroalkane (HFA) Beclometasone (BDP) Compared With Fluticasone Propionate (FP) in the Management of Asthma in a Representative Population in the United States (US)

Sponsor: Research in Real-Life Ltd

Conditions Asthma

Interventions Fluticasone propionate extra-fine hydrofluoroalkane beclometasone dipropionate

Updated 7 times since 2017 Last updated: Aug 2, 2013 Started: Jan 31, 2004 Primary completion: Dec 31, 2008 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Asthma and is currently completed. Research in Real-Life Ltd leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2022 — Jul 2024 [monthly]

Completed
Jan 2021 — Jan 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.
i3 Research

Data source: Research in Real-Life Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cawston, United Kingdom